This NINDS grant encourages early-stage development of novel small molecule or biologic therapeutics for Alzheimer’s and related dementias (ADRD). It specifically targets frontotemporal degeneration, Lewy body dementias, vascular contributions to cognitive impairment and dementia, and multiple etiology dementias. The program covers four stages, allowing applicants to enter at the appropriate point. The R61 phase supports preparatory research including in vitro/ex vivo assay development, therapeutic screening, and optimization with pharmacokinetic studies. The R33 phase advances research to in vivo efficacy studies in animal models. This funding aims to enable competitive follow-on applications for later-stage translational programs like Blueprint Neurotherapeutics Network, fostering critical early-stage discoveries for these debilitating neurological conditions.
Opportunity ID: 342896
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-22-059 |
| Funding Opportunity Title: | Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 02, 2022 |
| Last Updated Date: | Aug 02, 2022 |
| Original Closing Date for Applications: | Oct 31, 2022 |
| Current Closing Date for Applications: | Oct 31, 2022 |
| Archive Date: | Dec 06, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Public and State controlled institutions of higher education State governments For profit organizations other than small businesses Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Small businesses Independent school districts County governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer’s and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-059.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 342896 Full Announcement-RFA-NS-22-059 -> RFA-NS-22-059-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00276245 | Sep 30, 2022 | Oct 31, 2022 | View |
Package 1
Mandatory forms
342896 RR_SF424_5_0-5.0.pdf
342896 PHS398_CoverPageSupplement_5_0-5.0.pdf
342896 RR_OtherProjectInfo_1_4-1.4.pdf
342896 PerformanceSite_4_0-4.0.pdf
342896 RR_KeyPersonExpanded_4_0-4.0.pdf
342896 RR_Budget_3_0-3.0.pdf
342896 PHS398_ResearchPlan_4_0-4.0.pdf
342896 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342896 RR_SubawardBudget30_3_0-3.0.pdf
342896 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
